Jeanine Ballard

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

6

H-Index

1

About

Jeanine Ballard is a translational pharmacologist whose work focuses on the pharmacokinetic/pharmacodynamic (PK/PD) modeling of HIV latency reversal, a critical frontier in the quest to cure HIV. Her research centers on using automated, high-throughput platforms to evaluate novel histone deacetylase inhibitors (HDACis) as latency-reversing agents, aiming to "shock and kill" the dormant viral reservoir that persists despite antiretroviral therapy. Ballard’s key contribution lies in developing sophisticated in vitro PK/PD models that bridge preclinical drug screening and clinical application, enabling more precise prediction of how HDACis behave in the body to reactivate latent HIV. Her most-cited paper (2021, 6 citations) demonstrates this approach, highlighting the potential of automated systems to accelerate the discovery of effective latency reversal strategies. While her citation count is modest, her work is foundational in a niche but urgent area of HIV eradication research, offering a rigorous framework for evaluating novel compounds. Ballard’s achievements underscore her role in advancing the precision pharmacology needed to overcome the latent reservoir—a major barrier to a functional cure.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform
6 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago